the leadership of its previous director, Prof.
Nancy Ip, BRI has made great strides in its efforts to build
a leading state-of-the-art infrastructure for the advancement of
biotechnology. By leveraging its critical mass of multi-disciplinary
expertise, BRI's innovative research programs have begun to bear
fruits in recent years. BRI-supported projects have resulted in
a growing number of biomedical discoveries, and major efforts are
underway to commercially develop these inventions as therapeutic
agents for various diseases. In recognition of the potential of
these discoveries, The Hong Kong Jockey Club Charities Trust has
generously donated an additional HK$175 million to set up a biotechnology
company in partnership with HKUST to help bring viable drug candidates
from the laboratory into the clinical arena.
and strong commitment to excellence in research and development
has also led to an increasing awareness of the institute's competitiveness
within the international community. This has been a driving force
in the successful establishment of an extensive collaboration and
partnership network comprised of numerous high-profile and internationally
renowned scientists, academic organizations and biopharmaceutical
its initial results and growing recognition, BRI continues to strive
for excellence by consolidating and focusing its competitive strengths
and core competencies in order to stimulate the development of high
value strategic opportunities. I firmly believe that through the
concerted and integrated efforts of the public and private sectors,
a viable biotechnology industry can become a reality for the HKSAR.
Moreover, a thriving biotechnology sector would further contribute
towards the region's committed transformation into a high value-added
and knowledge-based economy.